IMBiologics Corp
493280
Company Profile
Business description
IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. Its proprietary IM-OpDECon platform enables the design of differentiated biologics targeting autoimmune diseases and immuno-oncology. The group leverages diverse antibody modalities to tackle critical unmet medical needs beyond the reach of current therapies. Its business areas are Antibody Research & Development and Autoimmune Diseases Immuno-Oncology. The group's pipeline products are IMB-101/102, IMB-201, and IMB-402.
Contact
260 Changnyong-daero
11th Floor, Gwanggyo Central Biz Tower
Yeongtong-gu, Iui-dong
Gyeonggi-do
Suwon-si
KORT: +82 3180678170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,782.50 | 16.90 | -0.19% |
| CAC 40 | 7,981.76 | 5.73 | -0.07% |
| DAX 40 | 24,400.65 | 92.73 | 0.38% |
| Dow JONES (US) | 49,363.88 | 322.24 | -0.65% |
| FTSE 100 | 10,330.55 | 6.80 | 0.07% |
| HKSE | 25,797.85 | 122.67 | 0.48% |
| NASDAQ | 25,870.71 | 220.02 | -0.84% |
| Nikkei 225 | 59,903.92 | 646.67 | -1.07% |
| NZX 50 Index | 12,837.56 | 136.76 | -1.05% |
| S&P 500 | 7,353.61 | 49.44 | -0.67% |
| S&P/ASX 200 | 8,558.10 | 15.00 | -0.17% |
| SSE Composite Index | 4,169.32 | 0.21 | -0.01% |